ERBB2 and neoplasm: Another case in a HER2-positive metastatic breast cancer patient with brain metastases also confirms CSF-derived ctDNA’s ability to harbor clinically relevant genomic alterations in patients with CNS metastases, making it an effective tool in tracking tumor evolution (33).